Carotid Artery Disease Market Share

Carotid Artery Disease Market Overview

Carotid Artery Disease Market Size was valued at USD 11.90 Billion in 2023. The Global Carotid Artery Disease industry is projected to grow from USD 12.40 Billion in 2024 to USD 17.30 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.10% during the forecast period (2024 - 2032). the growing demand for carotid artery disease natural treatment is pushing the market at a substantial rate. some of the factors that are driving the market growth are the growing population of the older populations, growing awareness for treatment for carotid artery disease. hence, the carotid artery stenosis market will have substantial growth.

In March 2024, Silk Road Medical introduced its tapered Enroute transcarotid stent system to hospitals in the USA. This new system builds upon the company's previous Enroute transcarotid stent system and provides more options to customize the transcarotid artery revascularization (TCAR) procedure based on the patient's anatomy. The introduction of the new tapered stent is a valuable enhancement to my TCAR toolbox, further distinguishing the company's primary product offering. 

Our company is at the forefront of stroke prevention, and we are dedicated to advancing our position in the minimally invasive treatment of carotid artery disease through our product development initiatives. The addition of new tapering configurations to our Enroute transcarotid stent system enhances the already extensive range of carotid treatments offered by Silk Road. TCAR is a surgical procedure that aims to offer the highest level of stroke prevention while minimizing negative outcomes in patients who need therapy for carotid artery stenosis. 

According to a press release from Silk Road, the Enroute transcarotid stent system is the sole transcarotid stent system currently on the market that is specifically recommended for patients who are at a high risk or standard risk of experiencing negative outcomes from carotid endarterectomy (CEA). The device has a cell design that is optimized to provide both lesion coverage and anatomical conformability, which helps stabilize plaques in the long run. It was specifically designed for TCAR and has a short delivery system that allows for precise and ergonomic stent distribution.

In July 2023, the US Centers for Medicare & Medicaid Services (CMS) released a preliminary version of a proposed national coverage determination (NCD) regarding carotid stenting. This indicates that CMS deems it appropriate and essential for Medicare patients with symptomatic carotid artery stenosis of at least 50% and those with asymptomatic carotid artery stenosis of at least 70%. 

CMS mandates the use of a stent that has been approved by the US Food and Drug Administration, along with an embolic protection device that has also been approved or cleared. Additionally, CMS strongly advocates for the implementation of formal shared decision-making processes before offering carotid stenting in clinical practice. Furthermore, independent neurological assessments are recommended both before and after the procedure. 

Although there is compelling evidence of equal uncertainty between carotid artery stenting (CAS) and carotid endarterectomy (CEA), this is the first instance in more than ten years that CMS has taken further deliberation on the coverage of carotid stenting beyond clinical trials and registries. The decision was made in accordance with a formal petition from the Multispecialty Carotid Alliance (MSCA), a group comprising experts in neurology, neuroradiology, neurosurgery, interventional radiology, vascular surgery, vascular medicine, and interventional cardiology.

Carotid arteries are basically the blood vessels that help in supplying oxygen-enriched blood to the brain. The vessels usually get blocked due to calcium, cholesterol, etc. Proper medication can help in clearing the blockage in the blood vessels and carotid arteries. The carotid artery disease market on the basis of region is divided into South America, North America, Europe, Asia-Pacific, and the Middle East and Africa. According to the MRFR analysis, North America will hold the dominant share in the carotid artery stenosis market. However, the Asia-Pacific region will grow at a substantial CAGR during the forecast period as well.

Furthermore, there are some restraints that can affect the market growth during the forecast period as well. The increasing costs of treatments and diagnosis for chronic diseases can slow down growth. Along with that, the slow diagnosis process and strict regulations can hamper the market growth. However, with the presence of several key players and the investments, the Carotid artery disease market will hold its position in the upcoming years.

Covid-19 Analysis Of Carotid Artery Disease Market

The prevalence of Coronavirus disease across the world had put a huge strain upon the Carotid artery disease market.  The growing number of affected patients with COVID-19 has affected the treatment of patients with other diseases. Also, it has put severe pressure on the economic condition of countries across the world. Due to border lockdowns in several countries, several factories were closed and it halted the production of various components used in the carotid artery disease and stenosis treatment. However, after the waiver on lockdowns, the market is reviving slowly and gradually. Thus, the carotid artery stenosis market is projected to regain its growth in the upcoming years.

Carotid Artery Disease Market Dynamics

Market Drivers

The major drivers for the carotid artery disease and stenosis treatment are the growing population of the older generation and the huge prevalence of unhealthy lifestyles. Apart from that, the increasing use of OTD or “over-the-counter drugs” will also fuel the carotid artery disease market growth in the upcoming period.

Restraints

There are some restraints that can reduce the carotid artery stenosis market growth in the upcoming years. One of the major restraints for the market is the strict regulations by the government for the treatment for carotid artery disease. Along with that, low availability of resources on the ground level can hamper market growth.

Opportunities

Some opportunities are projected to boost the market growth to a new level. Due to the growing awareness among patients for new technologies that help in early detection will open new opportunities for the market. Along with that, the improvement in treatments for stroke and heart attack will further boost the carotid artery disease market growth.

Challenges

Despite various growth opportunities, the carotid artery disease market will have some challenges. the increased cost for the carotid artery disease natural treatment will be a major challenge for people to diagnose and provide the treatment. thus, it can be a major factor affecting the carotid artery stenosis market.

Cumulative Analysis

The carotid artery disease market is estimated to have robust growth. the compound annual growth rate (CAGR) of the market is expected to grow at 4.1%. the market value is estimated to increase further up to usd 15,000 million in the forthcoming years. various factors are expected to fuel the carotid artery disease alternative treatment.

Value Chain Analysis

The carotid artery disease market will have a lucrative growth with various market developments. The growing investments by key players and the increasing prevalence of diseases related to cholesterol and heart will promote the carotid artery disease market extensively.

Carotid Artery Disease Market Segmentations

The segmentation of the carotid artery disease market is divided into end-user and type. on the basis of type, the carotid artery disease market is divided into surgery, medication, and diagnosis. the diagnosis segment is divided into Duplex Ultrasound, Compound Tomography, Magnetic Resonance Imaging, and others. On the basis of treatment, the carotid artery disease market is again divided into antihypertensive drugs, antiplatelet drugs, and cholesterol-lowering statins. On the basis of surgery, the market is again divided into carotid artery angioplasty, carotid artery bypass, and carotid endarterectomy. On the basis of end-user, the carotid artery disease market is divided into clinics and hospitals, pharmacies, ambulatory surgical centers.

Carotid Artery Disease Market Regional Analysis

The carotid artery disease market is divided into south america, north america, asia-pacific, europe, and the middle east and africa. north america is estimated to hold the largest share in the market in the forthcoming years. the growing rate of the older generation and cases of life-threatening diseases in countries such as the united states and canada will cause robust growth in the forthcoming years.

Apart from that, Europe and Asia-Pacific will also have a robust growth as compared to past years. The growing spends by the government of countries in these regions in the healthcare sector is the major driver for carotid artery disease and stenosis treatment. Also, the significant development in the infrastructure, treatment and new drugs will play a major role in the growth in these regions.

Carotid Artery Disease Market Competitive Landscape

Some of the major key players fuelling the growth of the Carotid artery disease market are as follows.

• Medtronic Plc


• Pfizer


• GE Healthcare


• Cardinal Health


• Eli Lily and Company


• AdvanceCor GmbH


• Teleflex, Siemens Healthcare


• Daiichi Sankyo Co. Ltd.


• Abbot Laboratories


• Bristol-Myers Squibb


• Merck & Cp. Inc.


• Silk Road Medical


• Stryker Corporation


• Hitachi


• Terumo Corporation


• Boston Scientific Corporation


• Dickinson Company


• L. Gore & Associates, Inc.

Recent Developments

• Boston Scientific Corporation in July 2018, announced the acquisition of Claret Medical Inc.


• Stryker Corporation in July 2018, renewed the “Pre-Market Approval” (PMA) from the FDA (Food and Drug Administration) of the United States.

Report Overview

The overview of the carotid artery disease and stenosis treatment market is as follows.

• Market Overview


• COVID-19 Analysis


• Dynamics of the Market


• Value Chain Analysis


• Market Segmentation


• Regional Analysis


• Competitive Analysis


• Recent Development

Report Score and Segmentation

• Study Period- 2021-2028


• Base Year-2021


• Forecast Period- 2021-2028


• Historical Period-2019-2020

The report score of the treatment for carotid artery disease market highlights the growth of the market in the forecast period 2021-2028. It highlights various factors such as opportunities, drivers, market value, etc., and notable key players that will push the market.

Segmentation

By Type

• Treatment


• Diagnosis


• Duplex Ultrasound


• Compound Tomography


• Magnetic Resonance Imaging


• Others

By Medications

• Antiplatelet Drugs


• Cholesterol-Lowering Statins


• Antihypertensive Drugs

By Surgical Procedures

• Carotid Artery Angioplasty


• Carotid Artery Bypass


• Carotid Endarterectomy

 By End-User

• Clinics and Hospitals


• Pharmacies


• Ambulatory Surgical Centres                                  

By Region

• North America


• Latin America


• Asia-Pacific


• Europe


• The Middle east Africa